US 12257242
Inhibition of crystal growth of roflumilast
granted A61KA61K31/44A61K45/06
Quick answer
US patent 12257242 (Inhibition of crystal growth of roflumilast) held by ARCUTIS BIOTHERAPEUTICS, INC. expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ARCUTIS BIOTHERAPEUTICS, INC.
- Grant date
- Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K31/44, A61K45/06, A61K47/10, A61K9/0014